These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30828784)

  • 1. Lookalike and soundalike drugs: a potential cause of cutaneous adverse reactions to drugs.
    Cassius C; Davis CJ; Bravard P; Carre-Gislard D; Modiano P; Lebrun-Vignes B; Ingen-Housz-Oro S; Chosidow O
    Br J Dermatol; 2019 Sep; 181(3):626-627. PubMed ID: 30828784
    [No Abstract]   [Full Text] [Related]  

  • 2. A 6-month prospective survey of cutaneous drug reactions in a hospital setting.
    Fiszenson-Albala F; Auzerie V; Mahe E; Farinotti R; Durand-Stocco C; Crickx B; Descamps V
    Br J Dermatol; 2003 Nov; 149(5):1018-22. PubMed ID: 14632808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004.
    Beyens MN; Guy C; Mounier G; Laporte S; Ollagnier M
    Drug Saf; 2008; 31(11):1017-26. PubMed ID: 18840021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.
    Laroche ML; Quelven I; Mazère J; Merle L
    Ann Pharmacother; 2015 Jan; 49(1):39-47. PubMed ID: 25366341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis.
    Zhao J; Hu L; Zhang L; Zhou M; Gao L; Cheng L
    An Bras Dermatol; 2019; 94(6):664-670. PubMed ID: 31789251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.
    Kim HK; Kim DY; Bae EK; Kim DW
    J Korean Med Sci; 2020 Feb; 35(4):e17. PubMed ID: 31997613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the cutaneous drugs reactions in a teaching hospital in Tunis].
    Souissi A; Fenniche S; Benmously R; Ben Jannet S; Marrak H; Mokhtar I
    Tunis Med; 2007 Dec; 85(12):1011-5. PubMed ID: 19170378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication errors through a national pharmacovigilance database approach: a study for Malta.
    Tanti A; Camilleri M; Bonanno PV; Borg JJ
    Int J Risk Saf Med; 2013 Jan; 25(1):17-27. PubMed ID: 23442294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
    Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
    Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing safety profile of avocado-soybean unsaponifiables].
    Olivier P; Montastruc JL;
    Presse Med; 2010 Oct; 39(10):e211-6. PubMed ID: 20937576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse consequences of low-dose methotrexate medication errors: data from French poison control and pharmacovigilance centers.
    Vial T; Patat AM; Boels D; Castellan D; Villa A; Theophile H; Torrents R; Kassai B
    Joint Bone Spine; 2019 May; 86(3):351-355. PubMed ID: 30243781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse reactions to lenalidomide.
    Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
    Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system.
    Magro L; Arzenton E; Moretti U; Sottosanti L; Potenza S; Leone R
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):69-75. PubMed ID: 27875920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication Errors Associated With Adverse Drug Reactions in Iran (2015-2017): A P-Method Approach.
    Karimian Z; Kheirandish M; Javidnikou N; Asghari G; Ahmadizar F; Dinarvand R
    Int J Health Policy Manag; 2018 Dec; 7(12):1090-1096. PubMed ID: 30709084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Ding WY; Lee CK; Choon SE
    Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adverse effects and medication errors: incidence and role of the organization of drug distribution].
    Piquet C; Mallaret M; Bontemps H; Fabre M; Sarrot-Reynaud F; Imbert B
    Therapie; 1999; 54(1):49-53. PubMed ID: 10216422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Skin changes with chemotherapy].
    Branzan AL; Landthaler M; Szeimies RM
    Hautarzt; 2005 Jun; 56(6):591-602; quiz 603. PubMed ID: 15909151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database.
    Duron D; Blaise S; Cracowski JL; Roustit M; Khouri C
    J Am Acad Dermatol; 2021 Jul; 85(1):229-232. PubMed ID: 32781179
    [No Abstract]   [Full Text] [Related]  

  • 20. [Skin toxicity related to Percutalgine(®): analysis of the French pharmacovigilance database].
    Remy C; Barbaud A; Lebrun-Vignes B; Perrot JL; Beyens MN; Mounier G; Marsille F; Roy M; Mismetti P; Guy C
    Ann Dermatol Venereol; 2012 May; 139(5):350-4. PubMed ID: 22578338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.